GleamWall
中文EN

TMDX TransMedics Group, Inc.

Electromedical & Electrotherapeutic Apparatus · Nasdaq · SEC CIK 1756262 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY28.5%
TTM net income YoY57.4%
TTM EPS YoY48.0%
Revenue 3-yr CAGR56.0%
Net income 3-yr CAGR—

Margins

Gross margin58.6%
Operating margin11.9%
Net margin19.9%
FCF margin6.1%
EBITDA margin17.4%

Returns

ROE31.9%
ROA11.7%
ROIC (approx.)—
Asset turnover0.59x

Leverage & solvency

Liabilities / assets63.7%
Debt / equity0.00x
Current ratio4.53x
Interest coverage3.46x

Cash quality & payout

Operating cash flow / net income0.78x
Accruals ratio2.6%
Payout ratio—
Capex / revenue9.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$203.00M$189.95M$173.93M$160.76M$143.82M$157.37M$143.54M$121.62M
Cost of revenue$84.35M$76.75M$72.77M$67.35M$59.25M$60.78M$55.31M$49.61M
Gross profit$118.66M$113.20M$101.16M$93.41M$84.58M$96.59M$88.23M$72.01M
R&D expense$29.18M$31.63M$24.88M$20.70M$15.26M$15.93M$17.16M$16.46M
SG&A expense$61.33M$57.83M$62.98M$51.44M$46.02M$44.09M$43.62M$46.91M
Operating income$28.14M$23.74M$13.30M$21.27M$23.30M$36.57M$27.44M$8.64M
Interest expense$7.27M$7.22M$7.17M$3.35M$3.49M$3.48M$3.46M$3.57M
Pretax income$24.10M$19.41M$8.48M$21.63M$23.03M$36.18M$26.68M$6.99M
Income tax$7.03M$4.72M$1.17M-$83.75M-$1.29M$1.27M$994,000$132,000
Net income$17.07M$14.68M$7.32M$105.38M$24.32M$34.91M$25.68M$6.86M
EBITDA$38.98M$33.98M$25.16M$28.74M$30.15M$43.30M$33.58M$14.32M
EPS (basic)0.490.420.21—0.711.030.76—
EPS (diluted)0.460.410.20—0.660.920.70—
Weighted avg. shares (diluted)40.83M40.71M36.19M—40.75M40.56M39.91M—
Balance sheet
Cash & equivalents$511.40M$491.11M$480.18M$488.87M$466.67M$401.07M$310.64M$337.15M
Receivables$114.94M$104.14M$90.73M$84.28M$80.70M$104.85M$142.03M$97.72M
Inventory$58.37M$54.14M$49.89M$48.88M$44.51M$38.87M$43.38M$46.55M
Current assets$692.46M$651.12M$619.28M$637.78M$613.00M$558.13M$505.92M$497.22M
PP&E, net$376.49M$365.30M$361.57M$327.66M$313.02M$312.25M$311.24M$285.97M
Goodwill$18.02M$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M$11.55M
Intangibles$2.81M$0$0$1.95M$2.00M$2.05M$2.10M$2.15M
Total assets$1.52B$1.46B$1.43B$1.07B$946.03M$890.52M$837.53M$804.08M
Current liabilities$152.86M$98.28M$91.92M$89.31M$79.72M$56.62M$55.60M$59.91M
Short-term debt$54.82M$20.00M$15.00M$10.00M$5.00M———
Total liabilities$967.23M$946.34M$940.81M$595.27M$590.83M$572.42M$571.22M$575.47M
Shareholders' equity$550.71M$518.05M$494.01M$473.10M$355.20M$318.10M$266.31M$228.60M
Shares outstanding34.72M34.63M34.55M34.27M34.14M34.04M33.83M33.62M
Cash flow statement
Operating cash flow$36.00M$17.31M$24.53M$34.51M$69.57M$91.61M-$2.85M$19.66M
Capital expenditure$8.40M$7.09M$36.66M$15.51M$7.62M$9.07M$27.04M$13.61M
Free cash flow$27.60M$10.22M-$12.12M$19.00M$61.95M$82.53M-$29.89M$6.06M
Investing cash flow-$13.71M-$7.09M-$36.66M-$15.51M-$7.62M-$9.07M-$27.04M-$13.61M
Financing cash flow-$1.92M$970,000$3.76M$3.10M$3.64M$7.09M$3.03M$1.19M
Depreciation & amortization$10.84M$10.24M$11.86M$7.47M$6.85M$6.73M$6.14M$5.68M
Stock-based compensation$12.60M$8.61M$9.95M$9.39M$9.14M$9.37M$8.96M$10.77M

Free plan shows the latest 8 periods; Pro shows all 36 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.